High doses of purified influenza A virus hemagglutinin significantly augment serum and nasal secretion antibody responses in healthy young adults
- PMID: 7814484
- PMCID: PMC264085
- DOI: 10.1128/jcm.32.10.2468-2473.1994
High doses of purified influenza A virus hemagglutinin significantly augment serum and nasal secretion antibody responses in healthy young adults
Abstract
The reactogenicity and immunogenicity of purified influenza virus hemagglutinin (HA) vaccines administered intramuscularly were evaluated in two placebo-controlled clinical trials. A total of 139 healthy young adults were randomized to receive increasing doses of monovalent influenza A/Taiwan/1/86 (H1N1) virus HA (range, 0 to 405 micrograms per dose [study 1]). An additional 139 subjects were given increasing doses of a trivalent HA vaccine containing equal amounts of A/H1N1 virus, A/Shanghai/16/89 (H3N2) virus, and influenza B/Yamagata/16/88 virus HA (range, 0 to 135 micrograms of HA per strain, 0 to 405 micrograms per dose) or a standard dose of commercial influenza vaccine (study 2). Increasing doses of HA were associated with increasing frequencies of symptoms at the vaccination site early after vaccination, but all doses were well tolerated. Occurrence of systemic symptoms was unrelated to dose. Increasing the dose of HA resulted in increasingly higher postimmunization levels of serum hemagglutination inhibiting and neutralizing antibody levels versus influenza A/H1N1 virus in study 1 (P < 0.05); these enhanced responses persisted for up to 6 months. Nasal secretory immunoglobulin A and G antibody responses were assessed 2 weeks after immunization with monovalent H1N1 virus HA; the frequencies of significant responses also increased in a dose-related fashion. Similar increases in serum antibody levels were noted for both A/H1N1 and A/H3N2 viruses in study 2. These data provide a basis for proceeding with the evaluation of high doses of purified HA in the elderly.
Similar articles
-
Increasing doses of purified influenza virus hemagglutinin and subvirion vaccines enhance antibody responses in the elderly.Clin Diagn Lab Immunol. 1996 Sep;3(5):507-10. doi: 10.1128/cdli.3.5.507-510.1996. Clin Diagn Lab Immunol. 1996. PMID: 8877126 Free PMC article. Clinical Trial.
-
Systemic and local antibody responses in elderly subjects given live or inactivated influenza A virus vaccines.J Clin Microbiol. 1989 Dec;27(12):2666-71. doi: 10.1128/jcm.27.12.2666-2671.1989. J Clin Microbiol. 1989. PMID: 2592535 Free PMC article.
-
Influenza vaccines: the effect of vaccine dose on antibody response in primed populations during the ongoing interpandemic period. A review of the literature.Vaccine. 1993;11(9):892-908. doi: 10.1016/0264-410x(93)90375-8. Vaccine. 1993. PMID: 8212834 Review.
-
Development and persistence of local and systemic antibody responses in adults given live attenuated or inactivated influenza A virus vaccine.J Clin Microbiol. 1986 Jan;23(1):66-72. doi: 10.1128/jcm.23.1.66-72.1986. J Clin Microbiol. 1986. PMID: 3700610 Free PMC article.
-
Intranasal Inactivated Influenza Vaccines: a Reasonable Approach to Improve the Efficacy of Influenza Vaccine?Jpn J Infect Dis. 2016;69(3):165-79. doi: 10.7883/yoken.JJID.2015.560. Jpn J Infect Dis. 2016. PMID: 27212584 Review.
Cited by
-
[Health Technology Assessment: a value-based tool for the evaluation of healthcare technologies. Reassessment of the cell-culture-derived quadrivalent influenza vaccine: Flucelvax Tetra® 2.0].J Prev Med Hyg. 2023 Mar 2;63(4 Suppl 1):E1-E140. doi: 10.15167/2421-4248/jpmh2022.63.4s1. eCollection 2022 Dec. J Prev Med Hyg. 2023. PMID: 37034835 Free PMC article. Italian. No abstract available.
-
Review of Influenza Virus Vaccines: The Qualitative Nature of Immune Responses to Infection and Vaccination Is a Critical Consideration.Vaccines (Basel). 2021 Sep 1;9(9):979. doi: 10.3390/vaccines9090979. Vaccines (Basel). 2021. PMID: 34579216 Free PMC article. Review.
-
High dose trivalent influenza vaccine compared to standard dose vaccine in patients with rheumatoid arthritis receiving TNF-alpha inhibitor therapy and healthy controls: Results of the DMID 10-0076 randomized clinical trial.Vaccine. 2020 May 13;38(23):3934-3941. doi: 10.1016/j.vaccine.2020.04.002. Epub 2020 Apr 12. Vaccine. 2020. PMID: 32295718 Free PMC article. Clinical Trial.
-
Cell mediated immune responses following revaccination with an influenza A/H5N1 vaccine.Vaccine. 2016 Jan 20;34(4):547-554. doi: 10.1016/j.vaccine.2015.11.055. Epub 2015 Dec 4. Vaccine. 2016. PMID: 26657997 Free PMC article. Clinical Trial.
-
Safety, efficacy, and immunogenicity of Flublok in the prevention of seasonal influenza in adults.Ther Adv Vaccines. 2015 Jul;3(4):97-108. doi: 10.1177/2051013615595595. Ther Adv Vaccines. 2015. PMID: 26478817 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical